Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Epidemiology, detection, and management of NAFLD: a Latin American perspective

Dr Nahum Mendez-Sanchez - National Autonomous University of Mexico, Mexico City...

Epidemiology, detection, and management of NAFLD: a Latin American perspective ( Dr Nahum Mendez-Sanchez - National Autonomous University of Mexico, Mexico City, Mexico )

Optimisation of supportive, palliative and end of life care

Dr Zipporah Ali - Africa Organisation for Research & Training in Cancer, Kenya

Optimisation of supportive, palliative and end of life care ( Dr Zipporah Ali - Africa Organisation for Research & Training in Cancer, Kenya )

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R...

Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma ( Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA )

What is required to advance data ethics, data sharing, and Open Science across...

Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India

What is required to advance data ethics, data sharing, and Open Science across LMICs ( Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India )

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic...

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )

Consolidation therapy with blinatumomab improves OS in newly diagnosed patients...

Dr Mark Litzow - Mayo Clinic, Rochester, USA

Consolidation therapy with blinatumomab improves OS in newly diagnosed patients with B-Lineage ALL in MRD negative remission ( Dr Mark Litzow - Mayo Clinic, Rochester, USA )

Breast cancer in elderly patients: a clinicopathological review of a Nigerian...

Dr Funmilola Wuraola - Obafemi Awolowo University Teaching Hospital, Ilé-Ifẹ̀...

Breast cancer in elderly patients: a clinicopathological review of a Nigerian database ( Dr Funmilola Wuraola - Obafemi Awolowo University Teaching Hospital, Ilé-Ifẹ̀, Nigeria )

Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in...

Dr Sara Hurvitz - University of California, Los Angeles, USA

Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in patients with HER2 + mBC ( Dr Sara Hurvitz - University of California, Los Angeles, USA )

PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning

Dr Shernan Holtan - University of Minnesota, Minneapolis, USA

PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning ( Dr Shernan Holtan - University of Minnesota, Minneapolis, USA )

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response...

Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response in previously untreated CLL enriched for high-risk disease ( Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA )

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and...

Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and OS in patients with high-risk HR+, HER2-negative BC ( Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA )

Camizestrant may be superior to fulvestrant in patients with hormone receptor...

Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer ( Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain )

More from ecancer